Latest Version of Skyland PIMS® Advances IDBS' Mission to Accelerate BioPharma Manufacturing
Retrieved on:
Wednesday, April 20, 2022
Skyland PIMS version 4.2 introduces new capabilities to accelerate biopharma development and manufacturing by eliminating barriers to data and expanding statistical analysis to further enhance monitoring of processes across modalities, including cell and gene therapies, small molecule, and vaccines.
Key Points:
- Skyland PIMS version 4.2 introduces new capabilities to accelerate biopharma development and manufacturing by eliminating barriers to data and expanding statistical analysis to further enhance monitoring of processes across modalities, including cell and gene therapies, small molecule, and vaccines.
- Through its acquisition of Skyland PIMS, IDBS created the first BioPharma Lifecycle Management (BPLM) offering that supports therapies from process development through commercial manufacturing.
- The latest version of Skyland PIMS also makes it easier for users to generate insights from biopharma manufacturing data with new multiple regression analysis for batches that leverages the raw materials and product genealogy.
- Additionally, PIMS version 4.2 introduces a Box-Cox data transformation feature for normalizing manufacturing datasets to surface insights, bolster analysis, and identify processes or quality out of trend.